AKESO INC. O.N. (4RY) - Total Liabilities
Based on the latest financial reports, AKESO INC. O.N. (4RY) has total liabilities worth €7.05 Billion EUR (≈ $8.25 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AKESO INC. O.N. annual equity growth to track the company's year-over-year net asset growth rate.
AKESO INC. O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how AKESO INC. O.N.'s total liabilities have evolved over time, based on quarterly financial data.
AKESO INC. O.N. Competitors by Total Liabilities
The table below lists competitors of AKESO INC. O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toll Brothers Inc
NYSE:TOL
|
USA | $6.01 Billion |
|
CNH Industrial N.V.
NYSE:CNH
|
USA | $34.17 Billion |
|
Kuang Chi Technologies Co Ltd
SHE:002625
|
China | CN¥1.83 Billion |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
USA | $1.38 Billion |
|
H WORLD GROUP DL-00001
F:CL4
|
Germany | €51.53 Billion |
|
Postal Savings Bank of China Co Ltd
F:3YB
|
Germany | €17.52 Trillion |
|
BizLink Holding Inc
TW:3665
|
Taiwan | NT$33.42 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down AKESO INC. O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AKESO INC. O.N. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AKESO INC. O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AKESO INC. O.N. (2021–2025)
The table below shows the annual total liabilities of AKESO INC. O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.05 Billion ≈ $8.25 Billion |
+17.55% |
| 2024-12-31 | €6.00 Billion ≈ $7.02 Billion |
+28.72% |
| 2023-12-31 | €4.66 Billion ≈ $5.45 Billion |
+58.16% |
| 2022-12-31 | €2.95 Billion ≈ $3.45 Billion |
+93.24% |
| 2021-12-31 | €1.53 Billion ≈ $1.78 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more